127,61 0,00 (0,00%)
Dopo ore: 4:04PM EST
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Justin D. Gover||CEO & Exec. Director||1,19M||4,11M||1971|
|Mr. Scott M. Giacobello||Chief Financial Officer||743,33k||253,81k||1970|
|Mr. Douglas B. Snyder||Chief Legal Officer||787,02k||244,37k||1964|
|Dr. Volker Knappertz M.D., D.Sc.||Chief Medical Officer||830,47k||288,48k||1965|
|Mr. Christopher John Tovey||Chief Operating Officer||N/D||N/D||1965|
|Mr. Stephen D. Schultz||VP of Investor Relations||N/D||N/D||N/D|
|Ms. Tina St. Leger||Chief HR Officer||N/D||N/D||N/D|
|Prof. Ben Whalley||Head of Discovery Research||N/D||N/D||N/D|
|Mr. Darren S. Cline||U.S. Chief Commercial Officer||N/D||N/D||1964|
|Mr. Adam David George||MD of UK & Company Sec.||N/D||N/D||1970|
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
L'ISS Governance QualityScore di GW Pharmaceuticals plc al 1 novembre 2019 è 4. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 5.